Olivares-Martínez, Elizabeth, Hernández-Ramírez, Diego Francisco, Núñez-Álvarez, Carlos Alberto et al. · International journal of molecular sciences · 2025 · DOI
Researchers tested a treatment called polymerized type I collagen (PTIC) in COVID-19 patients and found it may help reduce excessive inflammation by calming down immune cells called monocytes. The treatment appeared to improve breathing, reduce fatigue, chest pain, and cough in both the acute phase and long-term recovery from COVID-19. This finding could potentially be relevant for patients with long COVID or ME/CFS, which involve similar inflammatory problems.
ME/CFS shares underlying mechanisms with long COVID, including persistent STAT1-driven immune dysregulation and elevated pro-inflammatory cytokines. If PTIC's mechanism of action in reducing STAT1-mediated inflammation proves effective, it could offer a novel therapeutic approach for ME/CFS patients suffering from post-exertional malaise, fatigue, and dysautonomia. This study provides preliminary evidence that targeting specific immune receptors may help rebalance the inflammatory state characteristic of these conditions.
This study does not definitively prove that PTIC is effective for ME/CFS, as the patient cohort consisted only of COVID-19 outpatients, not ME/CFS patients. The correlational nature of the clinical findings does not establish causation—the observed symptom improvement could result from natural viral clearance or other concurrent treatments rather than PTIC alone. No placebo-controlled randomized trial is presented, and the abstract does not specify whether patients had documented post-exertional malaise or met formal ME/CFS diagnostic criteria.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Olivares-Martínez, Elizabeth, Hernández-Ramírez, Diego Francisco, Núñez-Álvarez, Carlos Alberto, Meza-Sánchez, David Eduardo, Chapa, Mónica, Méndez-Flores, Silvia, et al. (2025). Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.. International journal of molecular sciences. https://doi.org/10.3390/ijms26031018
BibTeX
@article{mecfsatlas-olivares-martnez-2025-polymerized-type,
author = {Olivares-Martínez, Elizabeth and Hernández-Ramírez, Diego Francisco and Núñez-Álvarez, Carlos Alberto and Meza-Sánchez, David Eduardo and Chapa, Mónica and Méndez-Flores, Silvia and Priego-Ranero, Ángel and Azamar-Llamas, Daniel and Olvera-Prado, Héctor and Rivas-Redonda, Kenia Ilian and Ochoa-Hein, Eric and López-Mosqueda, Luis Gerardo and Rojas-Castañeda, Estefano and Urbina-Terán, Said and Septién-Stute, Luis and Hernández-Gilsoul, Thierry and Aguilar-León, Diana and Torres-Villalobos, Gonzalo and Furuzawa-Carballeda, Janette},
title = {Polymerized Type I Collagen Downregulates STAT-1 Phosphorylation Through Engagement with LAIR-1 in Circulating Monocytes, Avoiding Long COVID.},
journal = {International journal of molecular sciences},
year = {2025},
doi = {10.3390/ijms26031018},
note = {PubMed: 39940787},
url = {https://www.mecfsatlas.com/evidence/olivares-martnez-2025-polymerized-type},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-27. https://www.mecfsatlas.com/evidence/olivares-martnez-2025-polymerized-type
Contribute
Private, reviewed by a human. Not a public comment thread.